搜尋
Celularity Inc
CELU添加自選
0.600USD
+0.002+0.37%
交易中 （美東）報價延遲15分鐘
17.31M總市值
虧損本益比TTM
關鍵數據
0.600今開
0.630最高
37.73K成交量
虧損本益比TTM
--本益比動
--股利TTM
0.13%換手率
0.598昨收
0.600最低
18.95K成交額
虧損本益比靜
-0.45市淨率
0.00%股息率 TTM
-76.43%ROA
4.35052週最高
0.28量比
-57.89M淨利潤
28.84M總股本
-3.5861每股盈餘TTM
0.47Beta
-6372.60%ROE
0.71052週最低
5.02%振幅
-88.86%毛利率
17.31M總市值
-7.48回報/風險
5.90%風險率
TradingKey Celularity Inc股票評分
單位: USD 更新時間: 2026-06-30操作建議
Celularity Inc當前公司基本面數據相對穩定，增長潛力較大。當前估值合理，在藥品行業排名124/157位。機構持股佔比非常高，近一月多位分析師給出公司評級為。最高目標價為6.00。中期看，股價處於下降通道。近一個月，市場表現非常差，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Celularity Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Celularity Inc亮點
亮點風險
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
業績高增長
公司營業收入穩步增長，連續3年增長16.60%
業績增長期
公司處於發展階段，最新年度總收入26.55M美元
估值高估
公司最新PE估值-0.17，處於3年歷史高位
機構減倉
最新機構持股3.75M股，環比減少6.45%
分析師目標
基於
0
分析師
--
評級
6.000
目標均價
+889.61%
漲幅空間
Celularity Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Celularity Inc簡介
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
公司代碼CELU
公司Celularity Inc
CEOHariri (Robert J)
網址https://celularity.com/
相關品種
-1.44%
-0.33%
-2.94%
-0.17%
-2.03%
-1.53%
-0.85%
+1.56%
-0.23%
-1.14%
+0.21%
-2.01%
-2.33%
-3.07%
+1.74%
0.00%
+0.41%
-2.09%
+0.46%
-0.68%熱門品種
52347.700
+151.400 (+0.29%)
29886.300
-338.300 (-1.12%)
7499.400
+17.000 (+0.23%)
15369.000
-226.000 (-1.45%)
69646.000
-1210.000 (-1.71%)
6280.700
-46.300 (-0.73%)
68.478
-1.443 (-2.06%)
294.620
+5.260 (+1.82%)
197.955
-2.135 (-1.07%)
4063.680
+56.400 (+1.41%)
常見問題
Celularity Inc(CELU)的當前股價是多少？
Celularity Inc(CELU)的當前股價是 0.60。
Celularity Inc 的股票代碼是什麼？
Celularity Inc的股票代碼是CELU。
Celularity Inc股票的52週最高點是多少？
Celularity Inc股票的52週最高點是4.35。
Celularity Inc股票的52週最低點是多少？
Celularity Inc股票的52週最低點是0.71。
Celularity Inc的市值是多少？
Celularity Inc的市值是17.31M。
Celularity Inc(CELU)股票的每股收益（EPS TTM）是多少
Celularity Inc(CELU)股票的每股收益（EPS TTM）是-3.59。